Literature DB >> 1397887

Frequency and significance of antibodies to liver/kidney microsome type 1 in adults with chronic active hepatitis.

A J Czaja1, M P Manns, H A Homburger.   

Abstract

To assess the frequency of antibodies to liver/kidney microsome type 1 (anti-LKM1) in patients with chronic active hepatitis, 131 such patients were tested by an indirect immunofluorescence assay. Of 62 patients with type 1 autoimmune hepatitis, none were seropositive. In contrast, 3 of 11 patients with autoimmune hepatitis and antimitochondrial antibodies (27%) were seropositive for anti-LKM1. Each had responded to corticosteroid therapy, and retesting of sera confirmed that each had been misclassified as antimitochondrial antibody positive. None of the patients with chronic active hepatitis B (14 patients) or C (24 patients) had anti-LKM1. Similarly, none of the 20 patients with cryptogenic disease had these antibodies. It is concluded that anti-LKM1 is specific for type 2 autoimmune hepatitis and is infrequent in adult patients seen at a referral center in the United States for chronic active hepatitis. Anti-LKM1 reactivity may be misinterpreted as antimitochondrial antibody reactivity by indirect immunofluorescence. Chronic hepatitis B and C virus infections are not important stimuli for the production of anti-LKM1, and testing for anti-LKM 1 is unlikely to clarify the nature of cryptogenic disease.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1397887     DOI: 10.1016/0016-5085(92)91518-9

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  37 in total

1.  Detection of liver kidney microsomal type 1 antibody using molecularly based immunoassays.

Authors:  N Kerkar; Y Ma; E T Davies; P Cheeseman; G Mieli-Vergani; D Vergani
Journal:  J Clin Pathol       Date:  2002-12       Impact factor: 3.411

2.  Isolation and characterization of cDNA encoding the antigenic protein of the human tRNP(Ser)Sec complex recognized by autoantibodies from patients withtype-1 autoimmune hepatitis.

Authors:  M Costa; J L Rodríguez-Sánchez; A J Czaja; C Gelpí
Journal:  Clin Exp Immunol       Date:  2000-08       Impact factor: 4.330

Review 3.  Autoantibodies as prognostic markers in autoimmune liver disease.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2010-05-13       Impact factor: 3.199

Review 4.  Global Disparities and Their Implications in the Occurrence and Outcome of Autoimmune Hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2017-07-14       Impact factor: 3.199

5.  The relationship between autoimmune markers and different clinical syndromes in autoimmune hepatitis.

Authors:  I G McFarlane
Journal:  Gut       Date:  1998-05       Impact factor: 23.059

Review 6.  Transitioning from Idiopathic to Explainable Autoimmune Hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2015-05-22       Impact factor: 3.199

7.  Genetic distinctions between autoimmune hepatitis in Italy and North America.

Authors:  Paolo Muratori; Albert-J Czaja; Luigi Muratori; Georgios Pappas; Silvana Maccariello; Fabio Cassani; Alessandro Granito; Rodolfo Ferrari; Vilma Mantovani; Marco Lenzi; Francesco-B Bianchi
Journal:  World J Gastroenterol       Date:  2005-03-28       Impact factor: 5.742

8.  High prevalence of non-organ-specific autoantibodies in hepatitis C virus-infected cirrhotic patients from southern Italy.

Authors:  Giovanni Squadrito; Marcello Previti; Marco Lenzi; Enrico Pagano Le Rose; Gaia Caccamo; Tea Restuccia; Enrico Di Cesare; Teresa Pollicino; Giovanni Raimondo
Journal:  Dig Dis Sci       Date:  2003-02       Impact factor: 3.199

9.  Frequency and significance of phenotypes for alpha1-antitrypsin deficiency in type 1 autoimmune hepatitis.

Authors:  A J Czaja
Journal:  Dig Dis Sci       Date:  1998-08       Impact factor: 3.199

10.  Prognosis and life expectancy in chronic liver disease.

Authors:  A Propst; T Propst; G Zangerl; D Ofner; G Judmaier; W Vogel
Journal:  Dig Dis Sci       Date:  1995-08       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.